Last reviewed · How we verify
Minoxidil Topical Foam
Minoxidil is a potassium channel opener that increases blood flow to hair follicles and prolongs the anagen (growth) phase of the hair cycle.
Minoxidil is a potassium channel opener that increases blood flow to hair follicles and prolongs the anagen (growth) phase of the hair cycle. Used for Androgenetic alopecia (male pattern baldness), Hair loss in women.
At a glance
| Generic name | Minoxidil Topical Foam |
|---|---|
| Sponsor | Eurofarma Laboratorios S.A. |
| Drug class | Potassium channel opener |
| Target | ATP-sensitive potassium channels |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 3 |
Mechanism of action
Minoxidil acts as a vasodilator by opening ATP-sensitive potassium channels, which increases cutaneous blood flow to hair follicles and delivers more oxygen and nutrients to promote hair growth. It also directly stimulates hair follicle growth and extends the duration of the anagen phase, shifting hairs from telogen (resting) to anagen (active growth) phase. The topical foam formulation allows for direct application to the scalp with improved absorption and patient compliance.
Approved indications
- Androgenetic alopecia (male pattern baldness)
- Hair loss in women
Common side effects
- Scalp irritation
- Pruritus
- Erythema
- Dryness
- Hypertrichosis (unwanted hair growth)
Key clinical trials
- Topical or Oral Minoxidil for the Treatment of Endocrine Therapy-Induced Alopecia in Patients With Stage I-IV Breast Cancer (EARLY_PHASE1)
- Clinical Trial to Evaluate CG2001 in Chinese Adult Male Participants With Androgenetic Alopecia (PHASE2)
- Treatment Results for Patients With Central Centrifugal Cicatricial Alopecia (CCCA): a Multicenter Prospective Study (PHASE4)
- Treatment of Androgenetic Alopecia in Men for 24 Weeks (PHASE3)
- Platelet Rich Plasma Versus Minoxidil Foam for Treatment of Androgenic Alopecia in Women (PHASE1, PHASE2)
- Minoxidil Response Testing in Females With Female Pattern Hair Loss
- Minoxidil Response Testing in Males With Androgenetic Alopecia
- A Study to Evaluate the Effectiveness and Safety of 5 Percent Minoxidil Foam in the Treatment of Male Pattern Hair Loss (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |